- Home
- NUVB vs DDI Comparison
NUVB vs DDI Comparison
Compare NUVB & DDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- DDI
- Stock Information
- Founded
- NUVB 2018
- DDI 2008
- Country
- NUVB United States
- DDI South Korea
- Employees
- NUVB N/A
- DDI N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- DDI EDP Services
- Sector
- NUVB Health Care
- DDI Technology
- Exchange
- NUVB Nasdaq
- DDI Nasdaq
- Market Cap
- NUVB 959.2M
- DDI 769.1M
- IPO Year
- NUVB N/A
- DDI 2021
- Fundamental
- Price
- NUVB $2.67
- DDI $10.78
- Analyst Decision
- NUVB Strong Buy
- DDI Strong Buy
- Analyst Count
- NUVB 6
- DDI 3
- Target Price
- NUVB $6.33
- DDI $22.67
- AVG Volume (30 Days)
- NUVB 2.7M
- DDI 58.8K
- Earning Date
- NUVB 11-06-2024
- DDI 02-11-2025
- Dividend Yield
- NUVB N/A
- DDI N/A
- EPS Growth
- NUVB N/A
- DDI N/A
- EPS
- NUVB N/A
- DDI 2.30
- Revenue
- NUVB $2,162,000.00
- DDI $342,458,000.00
- Revenue This Year
- NUVB N/A
- DDI N/A
- Revenue Next Year
- NUVB N/A
- DDI $1.30
- P/E Ratio
- NUVB N/A
- DDI $4.69
- Revenue Growth
- NUVB N/A
- DDI 13.42
- 52 Week Low
- NUVB $1.43
- DDI $7.16
- 52 Week High
- NUVB $4.16
- DDI $18.21
- Technical
- Relative Strength Index (RSI)
- NUVB 48.20
- DDI 31.31
- Support Level
- NUVB $2.51
- DDI $10.20
- Resistance Level
- NUVB $2.87
- DDI $12.65
- Average True Range (ATR)
- NUVB 0.17
- DDI 0.85
- MACD
- NUVB -0.02
- DDI -0.18
- Stochastic Oscillator
- NUVB 30.77
- DDI 14.68
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
About DDI DoubleDown Interactive Co. Ltd. American Depository Shares
DoubleDown Interactive Co Ltd is a developer and publisher of digital games on mobile and web-based platforms. The company is the creator of multi-format interactive entertainment experiences for casual players. Its market opportunity includes casual gaming globally, which includes slots, puzzles, cards, match three, and other similar games. Within the social casino segment of casual gaming, which includes free-to-play online slots, poker, table games, and bingo. Other games developed by the company are DoubleDown Fort, DoubleDown Classic, and Ellen's Road to Riches. The company has a presence in the international market, and it derives a majority of its revenue from the United States of America.